Plasminogen activator inhibitor 2 in menstrual endometrium and in primary cultures of endometrial cells

Fibrinolysis

Volumn 10, Issue 5-6, 1996, Pages 295-302

  Nordengren, J ^a   Casslen B ^a   Lecander, I ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTANOLONE; BASIC FIBROBLAST GROWTH FACTOR; EPIDERMAL GROWTH FACTOR; ESTRADIOL; GROWTH FACTOR; PLASMINOGEN ACTIVATOR INHIBITOR 2; PROGESTERONE; STEROID HORMONE; TRANSFORMING GROWTH FACTOR ALPHA;

ARTICLE; CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; ENDOMETRIUM CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MENSTRUATION; PRIORITY JOURNAL;

EID: 0030461653     PISSN: 02689499     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-9499(96)80010-5     Document Type: Article

References (35)

1. Andreasen P, Georg B, Lund L, Riccio A, Stacey S. Plasminogen activator inhibitors: hormonally regulated serpins. Mol Cell Endocrinol 1990; 68: 1-19.
2. Hart D A, Rehemtulla A. Plasminogen activators and their inhibitors: Regulators of extracellular proteolysis and cell function. Comp Biochem Physiol 1988; 90B: 691-708.
3. Astedt B, Lecander I, Ny T. The placental type plasminogen activator inhibitor, PAI 2. Fibrinolysis 1987; 1: 203-208.
4. Kawano T, Morimoto K, Uemura Y. Urokinase inhibitor in human placenta. Nature 1968; 217: 253-254.
5. Astedt B, Hägerstrand I, Lecander I. Cellular localisation in placenta of placental type plasminogen activator inhibitor. Thromb Haemost 1986; 56: 63-65.
6. Chapman H, Satone O. Characterization of a macrophagederived plasminogen-activator inhibitor. Biochem J 1985; 230: 109-116.
7. Wohlwend A, Belin D, Vassalli J-D. Plasminogen activatorspecific inhibitors produced by human monocytes/macrophages. JExpMed 1987; 165: 320-339.
8. Sumiyoshi K, Serizawa K, Urano T, Takada Y, Takada A, Baba S. Plasminogen activator system in human breast cancer. Int J Cancer 1992; 50: 345-348.
9. Pujade-Lauraine E, Lu H, Mirshahi S, et al. The plasminogenactivation system in ovarian tumors. Int J Cancer 1993; 55: 27-31.
10. Casslén B, Lecander I, Bossmar T, Astedt B. Plasminogen activator and plasminogen activator inhibitors in blood and tumor fluids of patients with ovarian cancer. Eur J Cancer 1994; 30A: 1302-1309.
11. Gleeson N, Gonsalves R, Bonnar J. The plasminogen activator urokinase and its inhibitor PAI-2 in endometrial cancer. Gynecol Oncol 1992; 47: 58-61.
12. Lecander I, Astedt B. Specific plasminogen activator inhibitor of placental type PAI 2 occurring in amniotic fluid and cord blood. J Lab Clin Med 1987; 110: 602-605.
13. Casslén B, Astedt B. Fibrinolytic activity of human uterine fluid. Acta Obstet Gynecol Scand 1981; 60: 55-58.
14. Casslén B, Thorell J, Astedt B. Effect of IUD on urokinase-like immunoreactivity and plasminogen activators in human uterine fluid. Contraception 1981; 23: 435-446.
15. Casslén B, Andersson A, Nilsson I, Astedt B. Hormonal regulation of the release of plasminogen activators and of a specific activator inhibitor from endometrial tissue in culture. Proc Soc Exp Biol Med 1986; 182: 419-424.
16. Casslén B, Urano S, Ny T. Progesterone regulation of plasminogen activator inhibitor 1 (PAI-1) antigen and mRNA levels in human endometrial stromal cells. Thromb Res 1992; 66: 75-87.
17. Casslén B, Urano S, Lecander I, Ny T. Plasminogen activators in the human endometrium, cellular origin and hormonal regulation. Blood Coag Fibrinolys 1992; 3: 133-138.
18. Rybo G. Plasminogen activators in the endometrium. Acta Obstet Gyn Scand 1966; 45: 97-118.
19. Koh S C L, Wong P C, Yuen R, Chua S E, Ng B L, Ratnam S S. Concentration of plasminogen activators and inhibitor in the human endometrium at different phases of the menstrual cycle. Journal of Reproduction & Fertility 1992; 96: 407-413.
20. Astedt B, Lecander I, Brodin T, Lundblad A, Low K. Purification of a specific placenta! plasminogen activator inhibitor by monoclonal antibody and its complex formation with plasminogen activator. Thromb Haemost 1985; 122-125.
21. Noyes R W, Hertig A T, Rock J. Dating the endometrial biopsy. Fertil Steril 1950; 1:3-25.
22. Casslén B. Proteinases and proteinase inhibitors in uterine fluid, with special reference to ILTD-users. Acta Obstet Gynecol Scand 1981; 60: 1-38.
23. Casslén B, Siler-Khodr T, Harper M. Progesterone regulation of prolactin release from human endometrial stromal cells in culllture: Potential bioassay for progestational activity. Acta Endocrinol 1990; 122: 137-144.
24. Laemmli U K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-685.
25. Ny T, Hansson L, Astedt B. Isolation of cDNA for type-2 plasminogen activator inhibitor. Thromb Haemost 1987; 58: 14.
26. Cox K H, DeLeon D V, Angerer L M, Angerer R C. Detection of mRNA in sea urchin embryos by in situ hybridization using asymmetric RNA probes. DevBiol 1984; 101: 485-502.
27. Young W S. In situ hybridization histochemistry. In: Björklund A, Hökfelt T, Wouterlood F G, van den Pol A N, ed. Handbook of chemical neuroanatomy: Analysis of neuronal microcircuits and synaptic interactions. Elsevier Science Publishers E.V., 1990; 8.
28. Whitfleld H J, Brady L S, Smith M A, Mamalaki E, Fox R J, Herkenham M. Optimization of cRNA probe in situ hybridization methodology for localization of glucocorticoid receptor mRNA in rat brain: A detailed protocol. Cell Mol Neurobiol 1990; 10: 145-000.
29. Simmons D M, Arriza J L, Swanson L W. A complete protocol for in situ hybridization of messenger RNAs in brain and other tissues with radiolabeled single-stranded RNA probes. J Histotech 1989; 12: 169-000.
30. Jonasson A, Larsson B, Astedt B, Lecander I. Placenta! and decidual u-PA, t-PA, PAI-1 and PAI-2 concentrations, as affected by cervical dilatation with laminara tens or hegar dilators. Thromb Res 1989; 53: 91-97.
31. Casslén B, Kobayashi T K, Stormby N. Cyclic variation of the cellular components in human uterine fluid. J Reprod Fertil 1982; 66: 213-218.
32. Lea R, Clark D. Macrophages and migratory cells in endometrium relevant to implantation. Baillieres Clin Obstet Gynaecol 1991; 5: 25-59. 33. Schwanz B S, Monroe M C, Levin E G. Increased release of plasminogen activator inhibitor type 2 accompanies the human mononuclear cell tissue factor response to lipopolysaccharide. Blood 1988; 71: 734-741.
33. van Hinsbergh V, Kooistra T, Scheffer M, van Bockel J, van Muijen G. Characterization and fibrinolytic properties of human omental tissue mesothelial cells. Comparison with endothelial cells. Blood 1990; 75: 1490-1497.
34. Medcalf R L, Van den Berg E, Schleuning W D. Glucocorticoidmodulated gene expression of tissue- and urinary-type plasminogen activator and plasminogen activator inhibitor 1 and 2. J Cell Biol 1988; 106: 971-978.
35. Casslén B, Nordengren J, Gustavsson B, Nilbert M, Lund L R. Progesterone stimulates degradation of urokinase plasminogen activator (u-PA) in endometrial stromal cells by increasing its inhibitor (PAI-1) and surface expression of the u-PA receptor. J Clin Endocrinol Metab 1995; 80: 2776-2784.